Urinary Stress Hormones, Hypertension, and Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis

Supplemental Digital Content is available in the text. Psychosocial stress is a key contributing factor to the pathogenesis of hypertension and cardiovascular disease. We examined the association of urinary stress hormone levels with incident hypertension and cardiovascular events. This prospective cohort study included 412 adults (age 48–87 years) free of hypertension from the Multi-Ethnic Study of Atherosclerosis with measurements of urinary stress hormones (norepinephrine, epinephrine, dopamine, and cortisol). Multivariable Cox proportional hazard models were used to estimate the adjusted hazard ratio (aHR) of incident hypertension and cardiovascular events according to urinary stress hormone levels. The average age (SD) was 61.2 (9.1) years, and 50% were female. Over a median follow-up of 6.5 years, there was an increased risk of incident hypertension per doubling of norepinephrine (aHR, 1.31 [95% CI, 1.06–1.61]), epinephrine (aHR, 1.21 [95% CI, 1.03–1.41]), dopamine (aHR, 1.28 [95% CI, 1.00–1.64]), and cortisol (aHR, 1.23 [95% CI, 1.04–1.44]). The associations were generally stronger among participants <60 years than those ≥60 years, particularly for dopamine (P-for-interaction, 0.04) and cortisol (P-for-interaction, 0.04). Over a median follow-up of 11.2 years, there was an increased risk of incident cardiovascular events per doubling of cortisol (aHR, 1.90 [95% CI, 1.16–3.09]), but not for catecholamines. In this multiethnic population study, higher urinary stress hormone levels were associated with an increased risk of incident hypertension. Urinary cortisol levels were also associated with an increased risk of incident cardiovascular events. Our findings highlight a potentially important role of stress hormones in the prevention and treatment of hypertension and cardiovascular diseases.

[1]  ROBERT W. Johnson,et al.  Multisite , 2020, Professional WordPress® Plugin Development.

[2]  K. Watson,et al.  Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium , 2020, Hypertension.

[3]  M. Budoff,et al.  Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. , 2019, Atherosclerosis.

[4]  S. Lightman,et al.  Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility , 2018, Stress.

[5]  J. Spence,et al.  The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension , 2018, Annals of Internal Medicine.

[6]  Andrew Steptoe,et al.  Effects of stress on the development and progression of cardiovascular disease , 2018, Nature Reviews Cardiology.

[7]  Joseph M Pappachan,et al.  Pheochromocytomas and Hypertension , 2018, Current Hypertension Reports.

[8]  D. Cruz-Topete,et al.  Hypothalamic-Pituitary-Adrenal Axis Modulation of Glucocorticoids in the Cardiovascular System , 2017, International journal of molecular sciences.

[9]  A. Isidori,et al.  Complications of Cushing's syndrome: state of the art. , 2016, The lancet. Diabetes & endocrinology.

[10]  P. Sever,et al.  Urinary catecholamines and the relationship with blood pressure and pharmacological therapy , 2016, Journal of hypertension.

[11]  Martin Reincke,et al.  Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.

[12]  A. Sherwood,et al.  Association of Depressive and Anxiety Symptoms With 24-Hour Urinary Catecholamines in Individuals With Untreated High Blood Pressure , 2015, Psychosomatic medicine.

[13]  T. Seeman,et al.  Associations of socioeconomic and psychosocial factors with urinary measures of cortisol and catecholamines in the Multi-Ethnic Study of Atherosclerosis (MESA) , 2014, Psychoneuroendocrinology.

[14]  P. Hopkins,et al.  PREDICTORS OF PLASMA AND URINARY CATECHOLAMINE LEVELS IN NORMOTENSIVE AND HYPERTENSIVE MEN AND WOMEN , 2013, Journal of Human Hypertension.

[15]  A. Sherwood,et al.  Blood pressure dipping: ethnicity, sleep quality, and sympathetic nervous system activity. , 2011, American journal of hypertension.

[16]  I. Chiodini Diagnosis and Treatment of Subclinical Hypercortisolism , 2011 .

[17]  P. Jose,et al.  Dopamine Receptors: Important Antihypertensive Counterbalance Against Hypertensive Factors , 2011, Hypertension.

[18]  H. Jha,et al.  Plasma circulatory markers in male and female patients with coronary artery disease. , 2010, Heart & lung : the journal of critical care.

[19]  L. Scott,et al.  Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. , 2008, American journal of physiology. Renal physiology.

[20]  Moyses Szklo,et al.  Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2008, Archives of internal medicine.

[21]  P. Jose,et al.  The dopaminergic system in hypertension. , 2007, Clinical science.

[22]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[23]  Alexander Bucur,et al.  Cumulative biological risk and socio-economic differences in mortality: MacArthur studies of successful aging. , 2004, Social science & medicine.

[24]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[25]  M. Kikuya,et al.  Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study , 2002, Journal of hypertension.

[26]  G. Dibona,et al.  Sympathetic nervous system and the kidney in hypertension , 2002, Current opinion in nephrology and hypertension.

[27]  J. Whitworth,et al.  Cushing, cortisol, and cardiovascular disease. , 2000, Hypertension.

[28]  M. Lokhandwala,et al.  THE ROLE OF INTRARENAL NITRIC OXIDE IN THE NATRIURETIC RESPONSE TO DOPAMINE-RECEPTOR ACTIVATION , 2000, Clinical and experimental hypertension.

[29]  B. McEwen Protective and damaging effects of stress mediators. , 1998, The New England journal of medicine.

[30]  B. Morgenstern,et al.  Human blood pressure determination by sphygmomanometry. , 1993, Circulation.

[31]  G. Chrousos,et al.  The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. , 1992, JAMA.

[32]  P. Brennan,et al.  Urinary catecholamines in essential hypertension: results of 24-hour urine catecholamine analyses from patients in the Medical Research Council trial for mild hypertension and from matched controls. , 1985, The Quarterly journal of medicine.

[33]  D. Lake,et al.  An improved technique for extracting catecholamines from body fluids , 1985, Journal of Neuroscience Methods.

[34]  F. Fuchs,et al.  Does psychosocial stress cause hypertension? A systematic review of observational studies , 2009, Journal of Human Hypertension.

[35]  G. Brooks,et al.  Catecholamine response is attenuated during moderate-intensity exercise in response to the "lactate clamp" , 2005 .

[36]  Shumei Yang,et al.  Glucocorticoids and vascular reactivity. , 2004, Current vascular pharmacology.

[37]  T. Saruta,et al.  Increased urinary dopamine excretion in young patients with essential hypertension. , 1994, Clinical and experimental hypertension.